Latest On GlaxoSmithKline plc (GLAXF):
About GlaxoSmithKline plc (GLAXF):
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Merck KGaA; Lyell Immunopharma; Novartis; CEPI; Innovax and Xiamen University; VBI; Viome; Sanofi SA; and CureVac. The company also has an agreement with Vir Biotechnology, Inc for research and development of new therapies for influenza and other respiratory viruses. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
General
- Name GlaxoSmithKline plc
- Symbol GLAXF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-General
- Full Time Employees 94,066
- Fiscal Year EndDecember
- Web URLhttp://www.gsk.com
Valuation
- Trailing PE 35.54
- Forward PE 12.99
- Price/Sales (Trailing 12 Mt.) 1.9
- Price/Book (Most Recent Quarter) 4.43
- Enterprise Value Revenue 3.5
- Enterprise Value EBITDA 14.05
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate $103.84
- Next Year EPS Estimate $114.25
- Next Quarter EPS Estimate $28.95
- Profit Margin 17%
- Return on Assets 7%
- Return on Equity 33%
- Earnings Per Share $0.50
- Revenue Per Share $0
- Gross Profit 23.21 billion
- Quarterly Earnings Growth -1.8%
ESG Rating
Highlights
- Market Capitalization 88.84 billion
- PE Ratio 14.1
- PEG Ratio 8.77
- Book Value Per Share $1.20
Share Statistics
- Shares Outstanding 5.03 billion
- Shares Float 4.89 billion
- % Held by Insiders 90%
- % Held by Institutions 50.82%
Technicals
- Beta 0.35
- 52 Week High $20.83
- 52 Week Low $14.17
- 50 Day Moving Average 17.5
- 200 Day Moving Average 18.28
Dividends
- Forward Annual Dividend Rate $1.07
- Forward Annual Dividend Yield 5.96%
- Payout Ratio 4%
- Dividend Date 2016-04-14
- ExDividend Date 2021-02-18
- Dividend Per Share $1.06
- Dividend Yield 0%
GlaxoSmithKline plc (GLAXF) Dividend Calendar:
GLAXF's last dividend payment was made to shareholders on April 14, 2016.
GlaxoSmithKline plc pays out 4% of its earnings out as a dividend.
Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
---|
GlaxoSmithKline plc (GLAXF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
---|---|---|---|---|---|
2020-12-31 | 2020-12-31 | $N/A | $23.30 | $23.15 | 0.65% |
2020-09-30 | 2020-12-31 | $8.65 billion | $0.18 | $30.43 | -99.39% |
2020-06-30 | 2020-09-30 | $N/A | $0.32 | $20.00 | -98.41% |
2020-03-31 | 2020-06-30 | $9.09 billion | $0.56 | $32.15 | -98.27% |
2019-12-31 | 2020-03-31 | $11.81 billion | $0.39 | $25.63 | -98.49% |
2019-09-30 | 2019-12-31 | $11.54 billion | $0.34 | $33.61 | -98.98% |
2019-06-30 | 2019-09-30 | $9.92 billion | $0.38 | $25.46 | -98.5% |
2019-03-31 | 2019-06-30 | $10.04 billion | $0.25 | $25.24 | -99.03% |
2018-12-31 | 2019-03-31 | $10.46 billion | $0.22 | $27.52 | -99.21% |
2018-09-30 | 2018-12-31 | $10.55 billion | $0.31 | $32.70 | -99.05% |
2018-06-30 | 2018-09-30 | $9.61 billion | $0.37 | $25.83 | -98.56% |
2018-03-31 | 2018-06-30 | $10.14 billion | $0.12 | $24.28 | -99.52% |
2017-12-31 | 2018-03-31 | $10.31 billion | $0.16 | $25.87 | -99.4% |
2017-09-30 | 2017-12-31 | $10.41 billion | -$0.15 | $32.15 | -100.47% |
2017-06-30 | 2017-09-30 | $7.32 billion | $0.33 | $26.54 | -98.76% |
2017-03-31 | 2017-06-30 | $7.38 billion | -$0.05 | $24.53 | -100.2% |
2016-12-31 | 2017-03-31 | $7.59 billion | $0.27 | $25.04 | -98.93% |
2016-09-30 | 2016-12-31 | $0.06 | $29.84 | -99.78% | |
2016-06-30 | 2016-09-30 | $0.21 | $21.03 | -98.98% | |
2016-03-31 | 2016-06-30 | -$0.12 | $17.82 | -100.67% | |
2015-12-31 | 2016-03-31 | $0.08 | $18.08 | -99.54% | |
2015-09-30 | 2015-12-31 | -$0.11 | $19.21 | -100.56% | |
2015-06-30 | 2015-09-30 | $0.17 | $16.27 | -98.98% | |
2015-03-31 | 2015-06-30 | $0.05 | $17.58 | -99.72% | |
2014-12-31 | 2015-03-31 | $2.47 | $26.63 | -90.72% | |
2014-09-30 | 2014-12-31 | $0.33 | $24.10 | -98.62% | |
2014-06-30 | 2014-09-30 | $0.13 | $21.38 | -99.38% | |
2014-03-31 | 2014-06-30 | $0.23 | $20.73 | -98.89% | |
2013-12-31 | 2014-03-31 | $0.23 | $30.53 | -99.25% | |
2013-09-30 | 2013-12-31 | $0.84 | |||
2013-06-30 | 2013-09-30 | $0.32 | |||
2013-03-31 | 2013-06-30 | $0.32 | |||
2012-12-31 | 2013-03-31 | $0.30 | |||
2012-09-30 | 2012-12-31 | $0.28 | |||
2012-06-30 | 2012-09-30 | $0.36 | |||
2012-03-31 | 2012-06-30 | $0.39 | |||
2011-12-31 | 2012-03-31 | $0.42 | |||
2011-09-30 | 2011-12-31 | $0.39 | |||
2011-06-30 | 2011-09-30 | $0.43 | |||
2011-03-31 | 2011-06-30 | $0.35 | |||
2010-12-31 | 2011-03-31 | $0.48 | |||
2010-09-30 | 2010-12-31 | -$0.21 | |||
2010-06-30 | 2010-06-30 | -$0.09 | |||
2010-03-31 | 2010-03-31 | $0.41 | |||
2009-12-31 | 2009-12-31 | $0.52 | |||
2009-09-30 | 2009-09-30 | $0.43 | |||
2009-06-30 | 2009-06-30 | $0.44 | |||
2009-03-31 | 2009-03-31 | $0.32 | |||
2008-12-31 | 2008-12-31 | $0.30 | |||
2008-09-30 | 2008-09-30 | $0.38 | |||
2008-06-30 | 2008-06-30 | $0.48 | |||
2008-03-31 | 2008-03-31 | $0.48 | |||
2007-12-31 | 2007-12-31 | $0.40 | |||
2007-09-30 | 2007-09-30 | $0.48 | |||
2007-06-30 | 2007-06-30 | $0.47 | |||
2007-03-31 | 2007-03-31 | $0.52 | |||
2006-12-31 | 2006-12-31 | $0.40 | |||
2006-09-30 | 2006-09-30 | $0.46 | |||
2006-06-30 | 2006-06-30 | $0.42 | |||
2006-03-31 | 2006-03-31 | $0.46 | |||
2005-12-31 | 2005-12-31 | $0.34 | |||
2005-09-30 | 2005-09-30 | $0.38 | |||
2005-06-30 | 2005-06-30 | $0.38 | |||
2005-03-31 | 2005-03-31 | $0.40 | |||
2004-06-30 | 2004-06-30 | $0.36 |
GlaxoSmithKline plc (GLAXF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
Date |
---|
Research Development |
Income Before Tax |
Selling General Administrative |
Gross Profit |
Ebit |
Operating Income |
Income Tax Expense |
Total Revenue |
Cost of Revenue |
Total Other Income Expense Net |
Net Income From Continuing Operations |
Net Income Applicable to Common Shares |
Cash Flow:
Date |
---|
Investments |
Change to Liabilities |
Total Cash Flow from Investing Activities |
Net Borrowings |
Total Cash Flow from Financial Activities |
Change to Operating Activities |
Change in Cash |
Total Cash from Operating Activities |
Depreciation |
Other Cash Flow from Investing Activities |
Change to Inventory |
Change to Account Receivables |
Other Cash Flow from Financing Activities |
Change to Net Income |
Capital Expenditures |
Balance Sheet:
Date |
---|
Total Liabailities |
Total Stockholder Equity |
Other Current Liabilities |
Total Assets |
Common Stock |
Other Current Assets |
Retained Earnings |
Other Liabilities |
Other Assets |
Cash |
Total Current Liabilities |
Other Stockholder Equity |
Property, Plant & Equipment |
Total Current Assets |
Long Term Investments |
Net Tangible Assets |
Short Term Investments |
Long Term Debt |
Inventory |
Accounts Payable |
GlaxoSmithKline plc (GLAXF) Chart:
GlaxoSmithKline plc (GLAXF) News:
Below you will find a list of latest news for GlaxoSmithKline plc (GLAXF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
GlaxoSmithKline plc (GLAXF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
---|
GlaxoSmithKline plc (GLAXF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
Date | Form Type | Form Name | Link |
---|